Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Epizyme stock | $4.55

Learn how to easily invest in Epizyme stock.

Epizyme Inc is a biotechnology business based in the US. Epizyme shares (EPZM) are listed on the NASDAQ and all prices are listed in US Dollars. Epizyme employs 304 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Epizyme

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – EPZM – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Epizyme stock price (NASDAQ: EPZM)

Use our graph to track the performance of EPZM stocks over time.

Epizyme shares at a glance

Information last updated 2021-10-23.
Latest market close$4.55
52-week range$4.45 - $14.30
50-day moving average $5.16
200-day moving average $6.93
Wall St. target price$11.14
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-2.53

Buy Epizyme shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
$20 per year
Financial advice powered by relationships, not commissions.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Epizyme stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Epizyme price performance over time

Historical closes compared with the close of $4.55 from 2021-10-22

1 week (2021-10-19) 1.11%
1 month (2021-09-24) -14.63%
3 months (2021-07-26) -31.37%
6 months (2021-04-26) -44.38%
1 year (2020-10-26) -63.97%
2 years (2019-10-25) -57.08%
3 years (2018-10-26) 8.93
5 years (2016-10-26) 9.05

Epizyme financials

Revenue TTM $32.6 million
Gross profit TTM $-100,238,000
Return on assets TTM -38.32%
Return on equity TTM -142.35%
Profit margin 0%
Book value $0.31
Market capitalisation $465.2 million

TTM: trailing 12 months

Shorting Epizyme shares

There are currently 8.6 million Epizyme shares held short by investors – that's known as Epizyme's "short interest". This figure is 4.6% down from 9.0 million last month.

There are a few different ways that this level of interest in shorting Epizyme shares can be evaluated.

Epizyme's "short interest ratio" (SIR)

Epizyme's "short interest ratio" (SIR) is the quantity of Epizyme shares currently shorted divided by the average quantity of Epizyme shares traded daily (recently around 865790.16064257). Epizyme's SIR currently stands at 9.96. In other words for every 100,000 Epizyme shares traded daily on the market, roughly 9960 shares are currently held short.

However Epizyme's short interest can also be evaluated against the total number of Epizyme shares, or, against the total number of tradable Epizyme shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Epizyme's short interest could be expressed as 0.08% of the outstanding shares (for every 100,000 Epizyme shares in existence, roughly 80 shares are currently held short) or 0.133% of the tradable shares (for every 100,000 tradable Epizyme shares, roughly 133 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Epizyme.

Find out more about how you can short Epizyme stock.

Epizyme share dividends

We're not expecting Epizyme to pay a dividend over the next 12 months.

Epizyme share price volatility

Over the last 12 months, Epizyme's shares have ranged in value from as little as $4.45 up to $14.3. A popular way to gauge a stock's volatility is its "beta".

EPZM.US volatility(beta: 1.18)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Epizyme's is 1.1815. This would suggest that Epizyme's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Epizyme overview

Epizyme, Inc. , a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma for adults and pediatric patients. It also develops Tazemetostat in combination with rituximab in patients with follicular lymphoma; R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma (DLBCL); and PARP inhibitor in patients with platinum-resistant solid tumors, such as small-cell lung cancer, triple-negative breast cancer, and ovarian cancer. In addition, it develops Tazemetostat in patients with castration-resistant prostate cancer; and adults and pediatrics with INI1-negative tumors. Further, the company develops pinometostat for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; PRMT5 inhibitor for patients with solid tumors; and PRMT1 inhibitor. Epizyme, Inc.

Frequently asked questions

What percentage of Epizyme is owned by insiders or institutions?
Currently 0.773% of Epizyme shares are held by insiders and 97.863% by institutions.
How many people work for Epizyme?
Latest data suggests 304 work at Epizyme.
When does the fiscal year end for Epizyme?
Epizyme's fiscal year ends in December.
Where is Epizyme based?
Epizyme's address is: 400 Technology Square, Cambridge, MA, United States, 02139
What is Epizyme's ISIN number?
Epizyme's international securities identification number is: US29428V1044
What is Epizyme's CUSIP number?
Epizyme's Committee on Uniform Securities Identification Procedures number is: 29428V104

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site